Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]- substance P: A pilot trial

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 7, 2010, Pages 1335-1344

  Cordier, D ^a   Forrer, F ^a   Bruchertseifer, F ^b   Morgenstern, A ^b   Apostolidis, C ^b   Good, S ^a   Muller Brand J ^a   Macke H ^a   Reubi, J C ^c   Merlo, A ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b JOINT RESEARCH CENTRE   (Italy)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

213Bi; Glioma; Substance P; Targeted therapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID SUBSTANCE P BI 213; CORTICOSTEROID; RADIOPHARMACEUTICAL AGENT; TEMOZOLOMIDE; UNCLASSIFIED DRUG; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; ORGANOMETALLIC COMPOUND; SINGLE HETEROCYCLIC RINGS; SUBSTANCE P; SUBSTANCE P, 213BI-DOTA(THIENYLALANYL(8)-METHIONYL(O2)(11))-;

ADULT; ARTICLE; ASTROCYTOMA; BLOOD SAMPLING; BRAIN BIOPSY; CANCER GRADING; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DRUG SYNTHESIS; EXTERNAL BEAM RADIOTHERAPY; FOCAL EPILEPSY; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIATION DOSE; RADIATION FIELD; RADIOISOTOPE THERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ALPHA RADIATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; FEASIBILITY STUDY; INJECTION; METABOLISM; MIDDLE AGED; PILOT STUDY; THERAPEUTIC USE; TREATMENT OUTCOME;

ADULT; ALPHA PARTICLES; FEASIBILITY STUDIES; GLIOMA; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INJECTIONS; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PILOT PROJECTS; SUBSTANCE P; TREATMENT OUTCOME;

EID: 77954952365     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1385-5     Document Type: Article

References (28)

1. Lacroix M, Abi-Said D, Fourney DR, Gikaslan ZL, Shi W, De Monte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95(2):190-8.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-96.
3. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosur-gery 2008;62(3):564-76. discussion 564-576.
4. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64. discussion 264-756.
5. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006;7(5):392-401.
6. Fahlbusch R, Nimsky C. Intraoperative MRI developments. Neurosurg Clin N Am 2005;16(1): xi-xiii.
7. Nimsky C, Ganslandt O, Fahlbusch R. Functional neuronaviga-tion and intraoperative MRI. Adv Tech Stand Neurosurg 2004;29:229-63.
8. Kaloshi G, Benouaich-Amiel A, Diakite F, Tallibert S, Lejeune J, Laigle-Donadey F, et al. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 2007;68(21):1831-6.
9. van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
10. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002;20(8):2076-84.
11. Stieber VW. Low-grade gliomas. Curr Treat Options Oncol 2001;2(6):495-506.
12. Hoang-Xuan K, Capelle L, Kujas M, Tallibert S, Duffau H, Lejeune J, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-8.
13. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980;30(9):907-11.
14. Hennig IM, Laissue JA, Horisberger U, Reubi JC. Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 1995;61(6):786-92.
15. Kneifel S, Cordier D, Good S, Ionescu MC, Ghaffari A, Hofer S, et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1, 4, 7, 10-tetraazacyclododecane-1-glutaric acid-4, 7, 10-triacetic acid-substance p. Clin Cancer Res 2006;12(12):3843-50.
16. Boyd M, Ross SC, Dorrens J, Fullerton NE, Tan KW, Zalutsky MR, et al. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides. J Nucl Med 2006;47(6):1007-15.
17. Raja C, Graham P, Abbas Rizvi SM, Song E, Goldsmith H, Thompson J, et al. Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 2007;6(6):846-52.
18. Allen BJ, Raja C, Rizvi S, Tsui W, Graham P, Thompson JF, et al. Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 2005;4(12):1318-24.
19. Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002;100(4):1233-9.
20. Apostolidis C, Molinet R, Rasmussen G, Morgenstern A. Production of Ac-225 from Th-229 for targeted alpha therapy. Anal Chem 2005;77(19):6288-91. (Pubitemid 41436964)
21. Apostolidis C, Molinet R, McGinley J, Abbas K, Mollenbeck J, Morgenstern A. Cyclotron production of Ac-225 for targeted alpha therapy. Appl Radiat Isot 2005;62(3):383-7. (Pubitemid 39655916)
22. Sangha H, Lipson D, Foley N, Salter K, Bhogal S, Pohani G, et al. A comparison of the Barthel Index and the Functional Indepen-dence Measure as outcome measures in stroke rehabilitation: patterns of disability scale usage in clinical trials. Int J Rehabil Res 2005;28(2):135-9.
23. Zielinska B, Apostolidis C, Bruchertseifer F, Morgenstern A. An improved method for the production of Ac-225/Bi-213 from Th-229 for targeted alpha therapy. Solv Extr Ion Exch 2007;25(3):339-49.
24. Bruchertseifer F G S, Apostolidis C, Mäcke H, Morgenstern A. An improved method for Bi-213 labelling of DOTA-/DOTAGA-chelated peptides. Eur J Nucl Med Mol Imaging 2006;33(S2): S161.
25. Merlo A, Hausmann O, Wasner M, Steiner P, Otte A, Jermann E, et al. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas. Clin Cancer Res 1999;5(5):1025-33.
26. Merlo A, Jermann E, Hausmann O, Chiquet-Ehrismann R, Probst A, Landolt H, et al. Biodistribution of 111In-labelled SCN-bz-DTPA-BC-2 MAb following loco-regional injection into glioblas-tomas. Int J Cancer 1997;71(5):810-6.
27. Schumacher T, Hofer S, Eichhorn K, Wasner M, Zimmerer S, Freitag P, et al. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med Mol Imaging 2002;29(4):486-93.
28. Nimsky C, von Keller B, Schlaffer S, Kuhnt D, Weigel D, Ganslandt O, et al. Updating navigation with intraoperative image data. Top Magn Reson Imaging 2009;19(4):197-204.